LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
Status:
Completed
Trial end date:
2020-06-08
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of LDE225 that
can be given in combination with everolimus to patients with esophageal or GEJ cancer. The
safety of the drug combination will also be studied.